Laparoscopy is not enough: full ERAS compliance is the key to improvement of short-term outcomes after colectomy for cancer.


Journal

Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653

Informations de publication

Date de publication:
05 2020
Historique:
received: 30 01 2019
accepted: 15 07 2019
pubmed: 7 8 2019
medline: 29 5 2021
entrez: 7 8 2019
Statut: ppublish

Résumé

The enhanced recovery after surgery (ERAS) programs and laparoscopic techniques both reduce hospital stay and postoperative morbidity in patients undergoing colorectal cancer surgery. Laparoscopic techniques are an integral part of the ERAS program. However, evidence showing that the implementation of a multimodal rehabilitation program in addition to laparoscopy for colonic cancer would improve postoperative outcomes is still lacking. This study aimed to evaluate the impact of ERAS program on postoperative outcomes after elective laparoscopic colonic cancer resection. This is a single-center observational study from a prospectively maintained database. Two groups were formed from all patients undergoing laparoscopic colonic surgery for neoplasm during a defined period before (standard group) and after introduction of an ERAS program (ERAS group). The primary endpoint was postoperative 90-day morbidity. Secondary endpoints were the total length of hospital stay, readmission rate, and compliance with ERAS protocol. A total of 320 patients were included in the analyses, with 160 patients in the standard group and 160 in the ERAS group. There were no differences in the baseline characteristics between the two groups. Overall morbidity was significantly lower in the ERAS group (21.25%) than that in the standard group (34.4%; OR = 0.52 [0.31-0.85], p < 0.01). This difference was not due to the reduction in major complications. Mean total hospital stay was significantly lower in the ERAS group (5.8 days) than that in the standard group (8.2 days, p < 0.01). There were no differences in readmission rates and anastomotic complications. The ERAS pathway reduced the overall morbidity rates and shortened the length of hospital stay, without increasing the readmission rates. A significant reduction in nonsurgical complications was evident, whereas no significant reduction was found for surgical complications.

Sections du résumé

BACKGROUND
The enhanced recovery after surgery (ERAS) programs and laparoscopic techniques both reduce hospital stay and postoperative morbidity in patients undergoing colorectal cancer surgery. Laparoscopic techniques are an integral part of the ERAS program. However, evidence showing that the implementation of a multimodal rehabilitation program in addition to laparoscopy for colonic cancer would improve postoperative outcomes is still lacking. This study aimed to evaluate the impact of ERAS program on postoperative outcomes after elective laparoscopic colonic cancer resection.
METHODS
This is a single-center observational study from a prospectively maintained database. Two groups were formed from all patients undergoing laparoscopic colonic surgery for neoplasm during a defined period before (standard group) and after introduction of an ERAS program (ERAS group). The primary endpoint was postoperative 90-day morbidity. Secondary endpoints were the total length of hospital stay, readmission rate, and compliance with ERAS protocol.
RESULTS
A total of 320 patients were included in the analyses, with 160 patients in the standard group and 160 in the ERAS group. There were no differences in the baseline characteristics between the two groups. Overall morbidity was significantly lower in the ERAS group (21.25%) than that in the standard group (34.4%; OR = 0.52 [0.31-0.85], p < 0.01). This difference was not due to the reduction in major complications. Mean total hospital stay was significantly lower in the ERAS group (5.8 days) than that in the standard group (8.2 days, p < 0.01). There were no differences in readmission rates and anastomotic complications.
CONCLUSIONS
The ERAS pathway reduced the overall morbidity rates and shortened the length of hospital stay, without increasing the readmission rates. A significant reduction in nonsurgical complications was evident, whereas no significant reduction was found for surgical complications.

Identifiants

pubmed: 31385073
doi: 10.1007/s00464-019-06987-5
pii: 10.1007/s00464-019-06987-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2067-2075

Références

Br J Surg. 2000 Nov;87(11):1540-5
pubmed: 11091243
Ann Surg. 2015 Jun;261(6):1153-9
pubmed: 25671587
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Arch Surg. 2009 Oct;144(10):961-9
pubmed: 19841366
Lancet Oncol. 2005 Jul;6(7):477-84
pubmed: 15992696
Dis Colon Rectum. 2011 May;54(5):535-44
pubmed: 21471753
Ann Surg. 2002 Dec;236(6):759-66; disscussion 767
pubmed: 12454514
Lancet. 2005 May 14-20;365(9472):1718-26
pubmed: 15894098
Colorectal Dis. 2012 Aug;14(8):1009-13
pubmed: 21985126
Dis Colon Rectum. 2013 May;56(5):667-78
pubmed: 23575408
World J Surg. 2013 Feb;37(2):259-84
pubmed: 23052794
Dis Colon Rectum. 2007 Feb;50(2):176-83
pubmed: 17180257
World J Surg Oncol. 2015 Dec 04;13:330
pubmed: 26637203
N Engl J Med. 2004 May 13;350(20):2050-9
pubmed: 15141043
J Dig Dis. 2014 Jun;15(6):306-13
pubmed: 24597608
Colorectal Dis. 2016 Feb;18(2):205-13
pubmed: 26299627
Ann Surg. 2017 Nov;266(5):729-737
pubmed: 28806303
World J Surg. 2014 Jun;38(6):1531-41
pubmed: 24368573
Br J Surg. 2005 Nov;92(11):1354-62
pubmed: 16237744
Ann Surg. 2011 Dec;254(6):868-75
pubmed: 21597360
Ann Surg. 2007 Jun;245(6):867-72
pubmed: 17522511
J Clin Oncol. 2014 Jun 10;32(17):1804-11
pubmed: 24799480

Auteurs

Hélène Meillat (H)

Department of Digestive Surgical Oncology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, 13009, Marseille, France. meillath@ipc.unicancer.fr.

Clément Brun (C)

Department of Anesthesiology and Critical Care, Institut Paoli Calmettes, Marseille, France.

Christophe Zemmour (C)

Inst Paoli Calmettes, Dept Clin Res & Invest, Biostat & Methodolo Unit, Marseille, France.
Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.

Cécile de Chaisemartin (C)

Department of Digestive Surgical Oncology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, 13009, Marseille, France.

Olivier Turrini (O)

Department of Digestive Surgical Oncology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, 13009, Marseille, France.

Marion Faucher (M)

Department of Anesthesiology and Critical Care, Institut Paoli Calmettes, Marseille, France.

Bernard Lelong (B)

Department of Digestive Surgical Oncology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, 13009, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH